Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On Decem♦ber 29, 2004, it was approved by FDA for the treatment of refra∏ctory or relapsed acute lymphoblastic leukemia (ALL) in chΩildren.

key word:

manufactured treatment

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives t∞o build a large health industry finance platform compan↕y integrating pharmaceutical, intelligent medical, bio pharmaceutical R&D, ind≤ustrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitraβtion reaction, sulfonation reaction, hydrogenation reaction, fluorination reπaction, chlorination reaction, bromination reaction, diazotization reaction, f∏ormat reaction, etc.

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On Dec✘ember 29, 2004, it was approved by FDA for the treatment of refractory or relapsed acuteε lymphoblastic leukemia (ALL) in children.

Clofarabine is the first new drug approved for pediatric ALLγ in the last 10 years. It can bring continuous remission to some children and create condition¥s for some children to receive bone marrow transplantation. It is a new effeδctive and well-tolerated treatment option for chil₩dren with high resistance leukemia. Clofarabine has also shown promise in children with rγelapsed or refractory acute myeloid leukemia.

Clofarabine HAS POTENTIAL BROAD SPECTRUM ANTITUMOR PROP±ERTIES: With more than 20 clinical indications in thβe United States, CLOfarabine is a broad spectrum anticancer drug with great potential.

Now in clinical indications are: breast, lung, colorectal, prostate, kidney cancer, c♥ervical cancer, pancreatic cancer, skin cancer, bladder cancer, non-small cell lung ca±ncer, oral cancer, nasopharyngeal carcinoma, laryngeal cancer, m×axillary sinus carcinoma, esophageal cancer, uterus tumor, melanoma, leiom✔yosarcoma of the bulk of the phase I clinical study has been done. Acute myelogeno>us leukemia, chronic lymphoma, and non-Hodgkin's l§ymphoma are in phase II clinical studies, and inhibition of graft rejection is in phase I cεlinical studies. So while it is used to treat acute leuke mia, its potential indications include many solid tumors as well as some immune diseases£.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) in∑hibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA a↑s the first DPP4 inhibitor for the treatment of type ⅱ dδiabetes mellitus. The characteristics of this drug a✔re that it can stimulate insulin secretion while reducing hunger witho£ut causing weight gain. Hypoglycemia and edema will not occur, and it is su✔itable for diabetic patients with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical♦ enterprise that is market-oriented and realizes industrial development through R&D inn ovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most im↓portant products for the treatment of arthritis. It is well tolerated and has a low incidence∞ of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor an¥tagonists. In clinical application, it has good thera÷peutic effect on atopic asthma and other types of bronchial asthm↔a, and the market prospect is huge. In the major category of asthma drugs, ₩leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmαaceutical enterprise that is market-oriented and realizes industrial dev♦elopment through R&D innovation and technology transformation↔.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA for Alzhαeimer's disease in the United States. Its treatment reaches t he target dose and has low toxic and side effects. It has been widely r£ecognized by our medical community, and good tolerance is its biggest advantage. In Octobe¶r 1999, Donepezil was launched in China under the trade nam≠e "Aricept", which is the main chemical drug against A‍lzheimer's disease. At present, CFDA has approved a number of domestic enterprises to pr∑oduce donepezil preparations, the main dosage forms are tablets, capsules, dispersive ×tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol- Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use ≤in the 27 EU member states. The world's first drug approved to∞ prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or knee rep"lacement. From June 2019 to June 2020, the annual sales of apixaban products overseas rea>ched about $15.4 billion, with a year-on-year growth of nearly 32%, and thπe API consumption reached about 23,960 kg, with a year∏-on-year growth of about 28%. Compared with its main competitor, Rivaroxaban, t$he drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-oriαented and realizes industrial development through R&D innovation and technology tr§ansformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufact≤ured by Genzyme. On December 29, 2004, it was appr∏oved by FDA for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in chil♦dren.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical e≤nterprise that is market-oriented and realizes industrial development through R&D innδovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technol•ogy Co., Ltd.